Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Phenotype and prognosis of primary sclerosing cholangitis-autoimmune hepatitis variant syndrome.

Created on 10 Oct 2026

Authors

Mirjam Kolev, Rahel Bütikofer, Yasemin Krucker, Pierre-Antoine Soret, Dominique Wendum, Lionel Arrivé, Mathilde Wagner, Olivier Chazouillères, Christophe Corpechot, Sara Lemoinne

Published in

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. Oct 09, 2026. Epub Oct 09, 2026.

Abstract

A subset of patients with primary sclerosing cholangitis (PSC) exhibits features of autoimmune hepatitis (AIH), referred to as PSC-AIH variant syndrome (VS). Data on the phenotype and prognosis of VS remain limited. We compared clinical characteristics and outcomes of patients with VS and PSC without VS (non-VS).
This retrospective cohort study included patients with PSC followed at a tertiary referral center. VS was defined as moderate-to-severe interface hepatitis on liver histology combined with at least one of the following: alanine aminotransferase ≥5 × upper limit of normal (ULN), IgG ≥1.5 × ULN, or smooth muscle antibody titer ≥1:80.
Twenty-eight patients with VS and 274 non-VS patients were included. At diagnosis, VS patients were younger (median 20 vs. 30 years, p < 0.001), less frequently had inflammatory bowel disease (46.4% vs. 77.7%, p = 0.001), and more often presented with cirrhosis (25% vs. 8%, p = 0.010). Median follow-up was 9.9 years. Adjusted transplant-free survival was similar between groups (HR 0.33, 95% CI 0.11-1.00; p = 0.051). After adjustment, VS was associated with a lower risk of liver-related events (HR 0.27, 95% CI 0.09-0.80; p = 0.019).
Despite more frequent cirrhosis at diagnosis, patients with VS had comparable transplant-free survival and lower adjusted hazard of liver-related events.

PMID:
42855375
Bibliographic data and abstract were imported from PubMed on 10 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 7
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement